Page 146 - 2019_05-HaematologicaMondo-web

M. Burke et al.
Blood. 1990;75(5):1170-1177.
17. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-posi- tive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009;27(31):5175-5181.
18. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003;17(4):700- 706.
19. Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromo- somes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999; 94(12):4036-4045.
20. Silverman LB, Gelber RD, Young ML, Dalton VK, Barr RD, Sallan SE. Induction
failure in acute lymphoblastic leukemia of
childhood. Cancer. 1999;85(6):1395-1404. 21. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal resid- ual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352
(9142):1731-1738.
22. Dworzak MN, Froschl G, Printz D, et al.
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952-1958.
23. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118(23):6043-6049.
24. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etopo-
side as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009;147(3):371-378.
25. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remis- sions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
26. Gokbuget N, Zugmaier G, Klinger M, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B- lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132-e135.
27. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1- PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013;31(25):e413- 416.
992
haematologica | 2019; 104(5)